INCY Stock Recent News

INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire.

FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.

Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without.

INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.

Stifel upgraded Incyte to Buy from Hold with a $107 price target.